右美托咪定
医学
镇静
麻醉
装载剂量
镇静剂
心动过缓
机械通风
咪唑安定
不利影响
重症监护室
作者
Wenfeng Cheng,Yinyin Chen,Faming He,Jingge Zhao,Zhengrong Mao,Bingyu Qin,Chunhua Hu,Shengnan Feng,Fan Zhang,Xin Dong,X Li,Baoquan Zhang,Ting Yue,Mian Zhang,Yibin Lu,Jian Chen,Xiaoye Jin,Yinjiang Chang,P L Chen,Lihui Wang
标识
DOI:10.1097/ccm.0000000000007011
摘要
OBJECTIVES: To evaluate whether remimazolam besylate could provide noninferior sedation to dexmedetomidine in patients under mechanical ventilation (MV) in the ICU. DESIGN: A multicenter, single-blind, randomized, noninferiority trial. SETTING: Fifteen ICUs across China between October 2021 and November 2023. PATIENTS: Adults under endotracheal intubation MV who were expected to require sedation for 8-48 hours. INTERVENTIONS: Three hundred fourteen patients were randomly assigned at a 1:1 ratio to the remimazolam besylate or dexmedetomidine group. Analgesia was provided via a continuous IV infusion of remifentanil at 1.2-9.0 µg/kg/hr. Remimazolam besylate or dexmedetomidine was administered IV at an initial loading dose of 0.1 mg/kg followed by a maintenance dose of 0.10-0.30 mg/kg/hr or at an initial loading dose of 0.20 µg/kg followed by a maintenance dose of 0.2-0.70 µg/kg/hr to achieve the targeted sedation range on the Richmond Agitation-Sedation Scale of -2 to +1. MEASUREMENTS AND MAIN RESULTS: Of the 314 patients enrolled, 299 completed the study. The sedation efficacy rates, as the primary endpoint, were 82.6% and 83.2% in remimazolam besylate and dexmedetomidine groups, respectively, in the per-protocol set (PPS), whereas the rate was 72.9% in both groups in the intention-to-treat (ITT) set. The noninferiority margin was set as 10%, and the lower limits of the two-sided 95% CI for the intergroup difference were -3.0% and -2.6% in the PPS and ITT sets, respectively. The dexmedetomidine group had a higher incidence of bradycardia than the remimazolam besylate group (4.7% vs. 0.7%; p = 0.029), whereas no intergroup differences were noted for the remaining secondary endpoints and adverse events. CONCLUSIONS: Remimazolam besylate could provide noninferior sedation as dexmedetomidine with a lower risk of bradycardia for 48 hours in mechanically ventilated patients in the ICU.
科研通智能强力驱动
Strongly Powered by AbleSci AI